Shopping Cart
- Remove All
- Your shopping cart is currently empty
Loxapine succinate (Loxapac), a D2DR and D4DR inhibitor, is utilized in schizophrenia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 mg | $33 | In Stock | |
100 mg | $47 | In Stock | |
200 mg | $76 | In Stock | |
500 mg | $167 | In Stock | |
1 mL x 10 mM (in DMSO) | $52 | In Stock |
Description | Loxapine succinate (Loxapac), a D2DR and D4DR inhibitor, is utilized in schizophrenia. |
Targets&IC50 | D2 receptor (human):24 nM(Ki), 5-HT2 (human):6.2 nM(Ki), 5-HT2 (bovine):6.6 nM(Ki), 5-HT2 (bovine):6.8 nM(Ki), D4 receptor (human):7.5 nM(Ki) |
In vitro | In rats, subcutaneous injection of Loxapine (0.3 mg/kg) induces general stiffness. In the rat brain, administering Loxapine (5 mg/kg) does not alter dopamine receptor density, but it reduces serotonin receptor density. |
In vivo | Loxapine effectively facilitates the binding of [3H]ketanserin to 5-HT2 receptors in both the human frontal cortex (ki=6.2 nM) and the bovine frontal cortex (ki=6.6 nM). Additionally, in LPS-activated mixed glial cells, loxapine at concentrations of 0.2 μM, 2 μM, and 20 μM, successfully reduces the secretion of IL-1β and IL-2. |
Alias | Loxapine succinate salt, Loxapac, Daxolin, Cloxazepin |
Molecular Weight | 445.9 |
Formula | C22H24ClN3O5 |
Cas No. | 27833-64-3 |
Smiles | OC(=O)CCC(=O)O.CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 2 mg/mL (4.48 mM) DMSO: 82 mg/mL (183.9 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.